• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Akebia Therapeutics (NQ: AKBA )

    1.690 +0.030 (+1.81%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Akebia Therapeutics

    < Previous 1 2 3 4 5 6 Next >
    Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
    In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount... 
    Via Benzinga
    Looking Into Akebia Therapeutics's Return On Capital Employed
    Via Benzinga
    Akebia Therapeutics Earnings Preview
    Akebia Therapeutics (NASDAQ:AKBA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Akebia... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
      Thursday saw 177 companies set new 52-week lows. 
    Via Benzinga
    Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
    You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? 
    Via TheNewswire.com
    Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
    You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?  
    Via Benzinga
    Akebia Therapeutics Return On Capital Employed Insights
      
    Via Benzinga
    Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
    Via Benzinga
    Akebia Therapeutics: Q2 Earnings Insights
    Akebia Therapeutics (NASDAQ:AKBA) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket
    Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,... 
    Via Benzinga
    Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket
    Gainers 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 31.4% to $0.2720 in pre-market trading after the company disclosed final results from Phase 2 VIBRANT study, End-of-Phase 2 meeting with the FDA for... 
    Via Benzinga
    How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
    By David Willey, Benzinga 
    Via News Direct
    How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
    Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
    Via TheNewswire.com
    Exposures Product Safety
    How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
    Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
    Via Benzinga
    Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Why Amazon Is Trading Higher By 12%: Here Are 23 Stocks Moving Premarket
    Gainers Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading. 
    Via Benzinga
    Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
    Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday. 
    Via Benzinga
    REV Stock Moves Amid Revlon Bankruptcy, Short Squeeze Hopes
    Revlon (REV) stock is on the move Friday as the volatility surrounding the meme stock continues following its bankruptcy announcement. 
    Via InvestorPlace
    U.S Stocks Turn Lower; Dow Tumbles Over 100 Points
    U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 100 points on Friday. 
    Via Benzinga
    Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
    Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
    Via Benzinga
    Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?
    Akebia Therapeutics (AKBA) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat. 
    Via InvestorPlace
    Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
    U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. 
    Via Benzinga
    The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Good morning, trader! It's time for another look at the biggest pre-market stock movers as we dive into the latest news for Friday! 
    Via InvestorPlace
    Akebia Therapeutics And 20 Stocks Moving Premarket
    Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday. 
    Via Benzinga
    Micron, Akebia Therapeutics And 3 Stocks To Watch Heading Into Friday
    Some of the stocks that may grab investor focus today are: 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Gainers 
    Via Benzinga
    Why Akebia Therapeutics Stock Is Soaring After Hours
    Akebia Therapeutics Inc (NASDAQ: AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with... 
    Via Benzinga
    Aspen Aerogels And 28 Stocks Moving Premarket
    Gainers 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.